SIC
XERS icon

SJS Investment Consulting’s Xeris Biopharma Holdings XERS Stock Holding History

SJS Investment Consulting’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$366 Buy
63
+44
+232% +$292 ﹤0.01% 1846
2025
Q4 		$150 Buy
+19
New +$150 ﹤0.01% 1877

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SJS Investment Consulting's XERS Position: Q1 2026 in Review

SJS Investment Consulting increased its Xeris Biopharma Holdings (XERS) stake by 232% in Q1 2026, buying an estimated $292 and bringing the position to 63 shares worth $366. The position accounts for ﹤0.01% of the portfolio, ranked #1846.

SJS Investment Consulting first reported a position in XERS in Q4 2025 and has held it in 2 quarters since. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • SJS Investment Consulting held 63 shares of Xeris Biopharma Holdings worth $366 as of Q1 2026.
  • SJS Investment Consulting bought 44 Xeris Biopharma Holdings shares in Q1 2026, an estimated $292.
  • Xeris Biopharma Holdings made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2026, its #1846 holding.
  • SJS Investment Consulting first reported a position in Xeris Biopharma Holdings in Q4 2025 and has held it in 2 quarters since.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.